glp 1 drugs and parkinson's disease A Big Week for GLP-1 - by Eric Topol The most extensive research to-date
Description
Studied up somewhat on the new bridge program for TFL enrollees
So its this vicious cycle
Manufacturers must invest in early benchtop process development to model and optimize their continuous chromatography system, ensuring its right-sized to keep pace with intensified upstream operations
A 72-week, double-blind phase 2 trial showed that once-daily administration of semaglutide had a significant therapeutic effect on NASH (193)
These improvements were noted in the exenatide treatment group compared with the control group of PD patients
Garrett Evensen, Edmund Pakhlevanyan, and April Williams of Salk
